Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a generally positive reception to the study, emphasizing the promising effects on glycemic control, weight loss, and management of hypercortisolism, as seen in phrases like 'major step for targeted care' and 'able to lower medications.' The tone is optimistic but balanced, referencing side effects such as hypokalemia, which tempers the overall enthusiasm but indicates recognition of meaningful clinical implications.
Most discussions are positive, highlighting the promising results of the study in improving glycemic control using mifepristone.
Participants show moderate interest, with mentions of improved health markers and hope for new treatments, but without deep technical engagement.
Comments cite specific findings like lower HbA1c and reduced weight, and some mention side effects, reflecting a medium level of conversation depth.
The discussions suggest potential for meaningful impact on treatment options for complex diabetes cases, but framing remains cautious.
Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia and mild GI effects. #ADAScisessions https://t.co/Bw1QAwYJGf https://t.co/UPBbFlvgg2
CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately controlled diabetes and hypercortisolism and has a manageable tolerability profile. @ADA_Pubs Read Here➡️ https://t.co/ZmKHBxh9fY https://t.co/wuTEbsR11j
Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
RT @AliceYYCheng: Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia…
This episode discusses new evidence on hypercortisolism prevalence in uncontrolled Type 2 Diabetes and the impact of treatment. The study shows significant glycemic improvements with mifepristone, a glucocorticoid…
This episode explores the case-based approach to managing hypercortisolism in uncontrolled diabetes, highlighting new evidence of its prevalence and treatment effects, supported by an independent educational grant from…
Accellacare PI, Dr. John Parker, worked on a newly published study in Diabetes Care. Adults with T2D + hypercortisolism saw improved glycemic control with mifepristone treatment—a major step for targeted care. Read more: https://t.co/JFvA0N10rG https://t.co/aQiWKZjzTQ
Mifepristone significantly improved glycemic control and reduced weight in diabetics with hypercortisolism, despite some participants discontinuing treatment. by DeFronzo RA, Fonseca V (...) Einhorn D et 23 al. in Diabetes Care https://t.co/du5ivPiJ8Y #MedX #MedResearch
(Diabetes Care) DM2 mal controlada e hipercortisolismo: mejora de la glucemia con el tratamiento con mifepristona. https://t.co/0U5Xdy55ud https://t.co/MG0PPKJnRH
RT @AliceYYCheng: Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia…
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
RT @DianaMIsaacs: Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
RT @DianaMIsaacs: Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
RT @AliceYYCheng: Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia…
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment | Diabetes Care | American Diabetes Association https://t.co/wIwedMdSkI
RT @AliceYYCheng: Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia…
RT @DianaMIsaacs: Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
RT @DianaMIsaacs: Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
Mifepristone study showed lower A1c, stable norm tension. Able to lower medications. Side effects as expected hypokalemia and mild GI effects. #ADAScisessions https://t.co/Bw1QAwYJGf https://t.co/UPBbFlvgg2
Catalyst 2 trial is published!! #ADA2025 #ADASciSessions https://t.co/QeDItV0Fel
Catalyst 2 trial is published!! https://t.co/QeDItV1d3T
RT @DiabetesCareADA: CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately con…
CATALYST treatment phase finds that treatment with mifepristone can improve HbA1c in individuals with inadequately controlled diabetes and hypercortisolism and has a manageable tolerability profile. @ADA_Pubs Read Here➡️ https://t.co/ZmKHBxh9fY https://t.co/wuTEbsR11j